New pill takes aim at Hard-to-Treat cancers
Disease control
Not yet recruiting
This study tests an experimental daily pill, FS-207, in people with advanced solid tumors that have a specific DNA feature called MSI-H. The goal is to see if the drug is safe, how the body processes it, and whether it can shrink or control the cancer. About 156 adults whose canc…
Phase: PHASE1 • Sponsor: Foresight Therapeutics (Hefei) Co., Ltd. • Aim: Disease control
Last updated Jun 16, 2026 12:50 UTC